title: Points of concern related to the micafungin versus caspofungin trial.
authors.forename: Edward H
authors.initials: EH
authors.lastname: Eiland
authors.forename: Ali
authors.initials: A
authors.lastname: Hassoun
authors.forename: Thomas
authors.initials: T
authors.lastname: English
mesh_terms: D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002175:Candida / Q000145:classification / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy*; D000077336:Caspofungin; D054714:Echinocandins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D055666:Lipopeptides; D008074:Lipoproteins / Q000009:adverse effects / Q000627:therapeutic use*; D000077551:Micafungin
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D000077336:Caspofungin; D000077551:Micafungin